Last reviewed · How we verify
NCT06991530
Effect of Low Molecular Weight Heparin in Freeze-thaw Embryo Transfer Cycles in Women With Recurrent Implantation Failure
trial testing Low Molecular Weight Heparine in Low Molecular Weight Heparin in 392 participants. Completed in 1 March 2025.
30 November 2024
Quick facts
| Lead sponsor | The Second Hospital of Shandong University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 392 |
| Start date | 1 January 2021 |
| Primary completion | 30 November 2024 |
| Estimated completion | 1 March 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Low Molecular Weight Heparine — full drug profile →
Conditions studied
- Low Molecular Weight Heparin — all drugs for Low Molecular Weight Heparin →
- Recurrent Implantation Failure — all drugs for Recurrent Implantation Failure →
- FET — all drugs for FET →
- IVF — all drugs for IVF →
Sponsor
The Second Hospital of Shandong University
Who can join
Adults 20 to 40, female only, with Low Molecular Weight Heparin or Recurrent Implantation Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Recurrent implantation failure (RIF) is considered a tough problem in assisted reproductive technology (ART) without effective treatments. The effect of low molecular weight heparin (LMWH) in pregnancy outcomes is controversial. In addition, there are few reports on the role of LMWH in population with RIF performing freeze-thaw embryo transfer (FET) cycles. The purpose of this study is to evaluate the effect of LMWH on pregnancy outcomes in women with FET cycles.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06991530
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Low Molecular Weight Heparine
Trials testing the same drug.
- NCT06913595 — Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery · Phase 1 · active not recruiting
Other The Second Hospital of Shandong University trials
Trials by the same sponsor.
- NCT07430579 — Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma · NA · recruiting
- NCT06337968 — CPB for Arthroscopic Hip Surgery · NA · not yet recruiting
- NCT06604091 — Cohort Profile：The Shandong Adenomyosis Cohort of Population Undergoing Reproductive Technology (SAart) · active not recruiting
- NCT06574958 — Clinical Study of CD38\CS1 Chimeric Antigen Receptor T Cells in the Treatment of Refractory/Recurrent Multiple Myeloma · EARLY_PHASE1 · active not recruiting
- NCT06572956 — Clinical Study on the Safety and Efficacy of CAR-T/CAR-NK Cells in the Treatment of Recurrent Refractory or Unresectable · EARLY_PHASE1 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06991530 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Second Hospital of Shandong University
- Last refreshed: 12 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06991530.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing